Shahrin Ahmed: Efficacy of CARVYKTI in multiple myeloma
Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared on X:
“The Phase III multi myeloma treatment trial is the subject of data from Johnson & Johnson – The second interim analysis data from Phase III was positive, as reported by Johnson & Johnson (J&J).
The purpose of the CARTITUDE-4 clinical trial of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) is to determine the efficacy of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) in treating multiple myeloma that has relapsed or has failed to respond to previous therapy.
Participants in the trial are adults with multiple myeloma that has relapsed and is resistant to lenalidomide, and have undergone one to three therapy lines before.
The study is conducted randomly to assess how effective and safe CARVYKTI is compared to standard treatments such as pills, boluses, and hydrocortisone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd).
In February 2022, CARVYKTI received FDA approval to treat adults who have relapsed or refractory multiple myeloma that has been treated with four or more prior therapeutic lines.
The indication now encompasses adults with relapsed or refractory multiple myeloma who have had at least one previous therapy line.
Those who are susceptible to lenalidomide due to the presence of a proteasome inhibitor and an immunomodulatory agent. CARVYKTI, a single infusion, is the first cell therapy to substantially enhance overall survival compared to standard treatment for myeloma patients in second-line settings.
A significant improvement in SjD activity in patients was found in the company’s monoclonal antibody nipocalimab from the Phase II DAHLIAS dose-ranging study, as reported by the company last month.”
Source: Shahrin Ahmed/X